GreenCandleCollector
## Recursion Pharmaceuticals (RXRX) Sees Bullish Analyst Reassessment – What's Behind the Rally?
Recursion Pharmaceuticals just got a shot in the arm from Wall Street. Analysts collectively lifted their one-year price target to **$7.14 per share**, up 10.53% from the previous $6.46 consensus. That might not sound dramatic, but here's the kicker: compared to RXRX's current market price of $4.26, the upside potential sits at a hefty **67.61%**. The range of individual analyst estimates spans from $3.03 on the bearish end to $11.55 on the optimistic side – showing divided opinion, though the cons
Recursion Pharmaceuticals just got a shot in the arm from Wall Street. Analysts collectively lifted their one-year price target to **$7.14 per share**, up 10.53% from the previous $6.46 consensus. That might not sound dramatic, but here's the kicker: compared to RXRX's current market price of $4.26, the upside potential sits at a hefty **67.61%**. The range of individual analyst estimates spans from $3.03 on the bearish end to $11.55 on the optimistic side – showing divided opinion, though the cons